Korean J Hematol 2009; 44(2):
Published online June 30, 2009
https://doi.org/10.5045/kjh.2009.44.2.67
© The Korean Society of Hematology
정성현 이현우 강석윤 안미선 황윤호 최진혁 김효철 조성란 박준성
아주대학교 의과대학 종양혈액내과학교실, 진단검사의학교실
Background: Acute leukemias co-expressing myeloid and lymphoid antigens but does not meet the criteria for biphenotypic acute leukemia (BAL) is common, however its clinical significance is not fully defined.
Methods: In this study, clinical features of 68 co-expressing (myeloid and lymphoid) acute leukemias diagnosed between January 2000 and December 2006 were studied and compared with those of a control group of patients (pure AML or ALL).
Results: Age, gender, initial Lactate dehydrogenase (LDH) level and cytogenetics were not different between the co-expressing group and the control group. But, the initial bone marrow blast percent was significantly higher in the co-expressing group (70% vs. 54.5%, P=0.003). Fifty five percent (16/29) of ALL and 30% (52/172) of AML patients showed myeloid and lymphoid markers concomitantly. The lymphoid antigen positive AML (Ly+ AML) patients showed significantly shorter survival rates than pure AML patients (4 year survival rate, 17.6% vs. 45.6%, P=0.002). However hematopoietic stem cell transplantation (HST) abrogated the difference (4 year survival rate, 54.7% vs. 50.6%, P=0.894). In ALL patients, survival rate was not affected by myeloid antigen co-expression (4 year survival rate 26.1% vs. 20%, P=0.954).
Conclusion: Co-expression of lymphoid markers in AML should be regarded as a poor prognostic factor and more aggressive treatment such as HST should be considered. (Korean J Hematol 2009;44:67-73.)
Keywords Acute leukemia, Immunophenotyping, Co-expression, Prognosis
Korean J Hematol 2009; 44(2): 67-73
Published online June 30, 2009 https://doi.org/10.5045/kjh.2009.44.2.67
Copyright © The Korean Society of Hematology.
정성현 이현우 강석윤 안미선 황윤호 최진혁 김효철 조성란 박준성
아주대학교 의과대학 종양혈액내과학교실, 진단검사의학교실
Seong Hyun Jeong, Hyun Woo Lee, Seok Yun Kang, Mi Sun Ahn, Yoon Ho Hwang, Jin Hyuk Choi, Hugh Chul Kim, Sung Ran Cho, Joon Seong Park
Departments of Hematology Oncology and Laboratory Medicine, Ajou University School of Medicine, Suwon, Korea
Background: Acute leukemias co-expressing myeloid and lymphoid antigens but does not meet the criteria for biphenotypic acute leukemia (BAL) is common, however its clinical significance is not fully defined.
Methods: In this study, clinical features of 68 co-expressing (myeloid and lymphoid) acute leukemias diagnosed between January 2000 and December 2006 were studied and compared with those of a control group of patients (pure AML or ALL).
Results: Age, gender, initial Lactate dehydrogenase (LDH) level and cytogenetics were not different between the co-expressing group and the control group. But, the initial bone marrow blast percent was significantly higher in the co-expressing group (70% vs. 54.5%, P=0.003). Fifty five percent (16/29) of ALL and 30% (52/172) of AML patients showed myeloid and lymphoid markers concomitantly. The lymphoid antigen positive AML (Ly+ AML) patients showed significantly shorter survival rates than pure AML patients (4 year survival rate, 17.6% vs. 45.6%, P=0.002). However hematopoietic stem cell transplantation (HST) abrogated the difference (4 year survival rate, 54.7% vs. 50.6%, P=0.894). In ALL patients, survival rate was not affected by myeloid antigen co-expression (4 year survival rate 26.1% vs. 20%, P=0.954).
Conclusion: Co-expression of lymphoid markers in AML should be regarded as a poor prognostic factor and more aggressive treatment such as HST should be considered. (Korean J Hematol 2009;44:67-73.)
Keywords: Acute leukemia, Immunophenotyping, Co-expression, Prognosis
Guen A Ko, Chan Jeoung Park, Kyung Ryung Kang, Ji Young Park, Young Suk Park, Hyun Chan Cho
Korean J Hematol 1999; 34(1): 52-61Huyn Sik Choi, Ki Youn Kim, Joong Won Lee, Jang Soo Suh, Won Kil Lee, Jay Sik Kim, Dong Seok Jean
Korean J Hematol 1997; 32(1): 86-97Sung-Hoon Jung, Youngil Koh, Min Kyoung Kim, Jin Seok Kim, Joon Ho Moon, Chang-Ki Min, Dok Hyun Yoon, Sung-Soo Yoon, Je-Jung Lee, Chae Moon Hong, Ka-Won Kang, Jihyun Kwon, Kyoung Ha Kim, Dae Sik Kim, Sung Yong Kim, Sung-Hyun Kim, Yu Ri Kim, Young Rok Do, Yeung-Chul Mun, Sung-Soo Park, Young Hoon Park, Ho Jin Shin, Hyeon-Seok Eom, Sang Eun Yoon, Sang Mee Hwang, Won Sik Lee, Myung-won Lee, Jun Ho Yi, Ji Yun Lee, Ji Hyun Lee, Ho Sup Lee, Sung-Nam Lim, Jihyang Lim, Ho-Young Yhim, Yoon Hwan Chang, Jae-Cheol Jo, Jinhyun Cho, Hyungwoo Cho, Yoon Seok Choi, Hee jeong Cho, Ari Ahn, Jong Han Choi, Hyun Jung Kim and Kihyun Kim
Blood Res 2025; 60():